Fujian Cosunter Pharmaceutical Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Guoping Li

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	13.2yrs
CEO ownership	5.7%
Management average tenure	no data
Board average tenure	6.9yrs

Recent management updates

Recent updates

Does Fujian Cosunter Pharmaceutical (SZSE:300436) Have A Healthy Balance Sheet?

Sep 30

Optimistic Investors Push Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) Shares Up 27% But Growth Is Lacking

Sep 30

Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Shares Climb 34% But Its Business Is Yet to Catch Up

Aug 12

Some Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) Shareholders Look For Exit As Shares Take 28% Pounding

Apr 16

CEO

Guoping Li (56 yo)

13.2yrs

Tenure

CN¥1,200,000

Compensation

Mr. Guoping Li is Chairman & General Manager of Fujian Cosunter Pharmaceutical Co., Ltd. He has been a Director of Fujian Cosunter Pharmaceutical Co., Ltd. since September 20, 2011.

Board Members

Name	Position	Tenure	Compensation	Ownership
Guoping Li	Chairman & GM	13.2yrs	CN¥1.20m	5.65% CN¥ 243.6m
Hongming Li	COO & Director	3.3yrs	CN¥1.74m	0.0054% CN¥ 232.7k
Fuhu Huang	Deputy GM & Director	8.2yrs	CN¥1.42m	0.0038% CN¥ 165.1k
Xiaohui Lin	Director	3.3yrs	CN¥460.80k	0.0027% CN¥ 117.2k
Liqing Ye	Non-Independent Director	13.2yrs	no data	8.5% CN¥ 366.3m
Yuan Li Li	Chairman of the Supervisory Board	6.9yrs	CN¥310.80k	no data
Guodong Li	Director	13.2yrs	CN¥421.20k	4.71% CN¥ 202.9m
Mingyu Chen	Independent Director	6.9yrs	CN¥150.00k	no data
Xinrong Qiang	Independent Director	6.9yrs	CN¥150.00k	no data
Hong Ren	Independent Director	3.8yrs	CN¥150.00k	no data
Hongjun Wu	Independent Director	less than a year	no data	no data
Chenming Zhuang	Non-Independent Director	less than a year	no data	no data

6.9yrs

Average Tenure

54.5yo

Average Age

Experienced Board: 300436's board of directors are considered experienced (6.9 years average tenure).

Fujian Cosunter Pharmaceutical Management

Management criteria checks 1/4

Key information

Recent management updates

Fujian Cosunter Pharmaceutical Co., Ltd. Announces Directorate Appointments

Fujian Cosunter Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Less than half of directors are independent

Less than half of directors are independent

Fujian Cosunter Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2022

Fujian Cosunter Pharmaceutical Co., Ltd. Announces Executive Appointments

Recent updates

Third quarter 2024 earnings released: CN¥0.22 loss per share (vs CN¥0.24 loss in 3Q 2023)

Does Fujian Cosunter Pharmaceutical (SZSE:300436) Have A Healthy Balance Sheet?

Optimistic Investors Push Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) Shares Up 27% But Growth Is Lacking

Fujian Cosunter Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: CN¥0.13 loss per share (vs CN¥0.59 loss in 2Q 2023)

Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Shares Climb 34% But Its Business Is Yet to Catch Up

New minor risk - Share price stability

Fujian Cosunter Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Fujian Cosunter Pharmaceutical Co., Ltd. Announces Directorate Appointments

Fujian Cosunter Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

First quarter 2024 earnings released: CN¥0.092 loss per share (vs CN¥0.40 loss in 1Q 2023)

Some Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) Shareholders Look For Exit As Shares Take 28% Pounding

Fujian Cosunter Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Fujian Cosunter Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Third quarter 2023 earnings released: CN¥0.24 loss per share (vs CN¥0.28 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.59 loss per share (vs CN¥0.11 loss in 2Q 2022)

First quarter 2023 earnings released: CN¥0.40 loss per share (vs CN¥0.057 loss in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.022 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: CN¥0.11 loss per share (vs CN¥0.14 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Fujian Cosunter Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2022

Third quarter 2021 earnings released: CN¥0.022 loss per share (vs CN¥0.026 profit in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.068 profit in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.11 (vs CN¥0.08 in FY 2019)

Fujian Cosunter Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day low: CN¥32.51

Fujian Cosunter Pharmaceutical Co., Ltd. Announces Executive Appointments

New 90-day high: CN¥37.19

Third quarter earnings released

Fujian Cosunter Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low: CN¥32.00

First half earnings released

Fujian Cosunter Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥38.35

Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) signed an equity transfer agreement to acquire an additional 10% stake in Jiangsu Zhongxing Pharm Co., Ltd from Pan Lifei and Pan Liqiang for CNY 5.3 million.

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age